SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Courtesy of Dana-Farber Cancer Institute
Business
Dana-Farber and Deerfield Join Forces Again in $130 Million Collab
The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient’s hands.
February 8, 2021
 · 
2 min read
 · 
Kate Goodwin
Biotech Bay
From Ancestry to Genetics-Based Drug Development, Richard Branson Takes 23andMe Public
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
February 5, 2021
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Study Suggests Flu Vaccine Protects Against Severe COVID-19 Infection in Children
Studies suggest the severity of COVID-19 infection may be lessened by flu vaccine.
February 4, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Life Sciences Dollars Flow Despite Global Recession
The economy is depressed, but investors are impressed with these life science companies.
February 4, 2021
 · 
4 min read
 · 
Kate Goodwin
Money on the Move: January 27 – February 2
A recap of where life sciences cash has been flowing the past week.
February 2, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
COVID-19 “Long-Haulers” Face Ongoing Health Battles
Medical community struggles over how to help patients with long-lasting, serious side effects even after “recovering” from COVID-19 infection.
February 2, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Biosimilars Company Switches Gears to Immuno-Oncology with $150 Million Deal
Junshi receives upfront payment of $50 million for U.S. and Canadian rights to its immuno-oncology drug.
February 1, 2021
 · 
2 min read
 · 
Kate Goodwin
Job Trends
Life Sciences Companies Growing in a Pandemic-Induced Depression
While companies around the globe reduce staff amidst economic upheaval, there’s at least one industry on the rise - life sciences. Here’s who’s breaking ground on expansion projects.
January 29, 2021
 · 
4 min read
 · 
Kate Goodwin
grandbrothers/Shutterstock
FDA
Approved! FDA Grants IND Clearance to Three More Candidates Today
The FDA is on a roll granting approvals. Three companies announced IND updates today.
January 28, 2021
 · 
3 min read
 · 
Kate Goodwin
Indiana Biosciences Research Institute Diabetes Ce
Business
IBRI Researchers Find Opportunity to Repurpose Drugs for Type 1 Diabetes
A team led by Dr. Decio Eizirik, M.D., Ph.D., Scientific Director for Indiana Biosciences Research Institute Diabetes Center, has taken a step back from the traditional immune system study approach and found potential for treatment and, theoretically, even a cure.
January 27, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Money on the Move: January 21-26
A brief rundown of who’s raking in cash in the biopharma world.
January 27, 2021
 · 
3 min read
 · 
Kate Goodwin
Job Trends
New Biopharma Job Expansions Help Ring in the New Year
While many industries are struggling, biopharma is booming. Here’s an overview of last month’s company expansion announcements, who’s growing their footprint and adding more jobs.
January 27, 2021
 · 
3 min read
 · 
Kate Goodwin
Photo courtesy of Wugen.
Business
Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer
The “Woogies” at Wugen have been busy these past three years. BioSpace sat down with CEO John McKearn, Ph.D. to find up what his company has been up to.
January 26, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Study: Eli Lilly’s COVID-19 Antibody Protects the Most Vulnerable from Infection
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.
January 21, 2021
 · 
2 min read
 · 
Kate Goodwin
BioForest
Money on the Move: January 15-20
A brief rundown of the biopharmas that brought in the cash the past week.
January 20, 2021
 · 
2 min read
 · 
Kate Goodwin
Load More